Genmab — April 2016
-
Og til sidst: We continue to like the Genmab investment case and we consider the rapidly
growing market as an incremental positive compared with our current assumptions.
It is vital that Genmab secures a positive outcome of the POLLUX trial (Darzalex
combined with Revlimid in relapsed/refractory MM patients), but we have no reason
to doubt this as previous trials in this setup all have been very positive. -
nice - jeg har SEB target på 1250 fra 08042016. De justerer ikke på det i samme åndedrag?
-
nej SEB beholder target 1250
-
tak
-
Ved valg af behandlingskombination er der i USA 3 parter: Læge, forsikringsselskab og patient. Selvfølgelig spiller responsdybden en stor rolle. Men det gør prisen også. Ikke mindst for forsikringsselskaberne. Så det er ikke utænkeligt at i visse tilfælde vil det ene stof blive fravalgt pga prisen.
-
Hold nu kæft for et luk i US.
-
Troede egentlig, at vi var all set til et forsøg på Ath i morgen og måske endda 1000 - men så kom den sidste time...
-
Uuups. Godt de ikke rigtig er onkologirelaterede....
-
God morgen.

-
Vores venner fra shaw justerer positionen til 0.69% af aktierne - de fastholder i det store hele deres position.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind